AgomAb Therapeutics
Posthoflei 1/6, 2600 Antwerp, Belgium
About the sponsor
The sponsor demonstrates a focused commitment to advancing therapeutic interventions in gastrointestinal malignancies, with particular emphasis on difficult-to-treat upper gastrointestinal cancers. Research efforts concentrate on addressing gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, two cancer types that represent significant unmet medical needs in oncology. The therapeutic approach targets patients with advanced or metastatic disease who have experienced progression following standard treatment regimens.
- Gastric Cancer
- Gastroesophageal Junction Tumors
- Advanced Stage Malignancies
The research portfolio specifically addresses patients whose disease has progressed after first-line platinum-based chemotherapy, representing a critical population with limited therapeutic options. This focus on refractory gastrointestinal cancers underscores the sponsor's dedication to developing innovative solutions for patients facing treatment resistance in upper digestive tract malignancies.
Try clearing a filter, or search the whole catalogue.
Are you running a clinical trial?
Increase visibility for your trials and help patients find your site through our platform.